T he study by Kalkhoran et al. 1 uses data from a smokingcessation trial to describe e-cigarette use among primary care patients. The study participants were recruited from patients in three primary care practices in San Francisco who were enrolled in a test of a tablet-based intervention. At baseline, they were asked questions about their use of ecigarettes and reasons for doing so. Of the 788 participants, 52% reported they had ever used an e-cigarette and 20% had used one in the last month. E-cigarette users tended to be younger than non-users, and use was least prevalent at the safety-net general internal medicine practice. Only 9% of current e-cigarette users reported using them daily, and 66% had used them on ≤5 days in the past month. Most e-cigarette users did not know the nicotine content of their devices; seeking assistance in cutting down or quitting conventional cigarettes and reducing harm were the most common reasons for use.
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In sum, although the study was limited to one West Coast city, these results are similar to other studies describing e-cigarette use in the general U.S. population. 2 The vast majority of e-cigarette users also smoke (or have smoked) conventional cigarettes, so this population is a reasonable one for focus. On a practical level, clinicians and health-care systems who ask about ecigarette use may uncover a population of smokers who want to quit, and this may open a discussion of evidence-based tools that can help (i.e. not necessarily e-cigarettes).
The perception of e-cigarettes as less harmful than conventional cigarettes demonstrates how powerful marketing and media can be, and should serve as a note of caution both for this product and for others to come. It was not until recently that we had solid evidence comparing e-cigarettes to conventional cigarettes in terms of carcinogen or toxin exposure, 3 and yet e-cigarette marketers were able to strongly impress upon the public that these devices were safer than conventional cigarettes. The use of such devices has skyrocketed in the U.S., and public-health messaging has been somewhat slow to solidify; we owe it to our patients to discuss both ecigarettes and conventional cigarettes routinely.
